Anthony Sonn

Clinical, Interventional, and Structural Cardiologist skilled at assessing conditions and devising treatments in line with latest research and treatment protocols.

• Fellow, American College of Cardiology
• Fellow, Society for Cardiovascular Angiography & Interventions

• American Board of Internal Medicine, Internal Medicine, 2003 - 2013
• American Board of Internal Medicine, Cardiovascular Disease, 2006 - Present
• American Board of Internal Medicine, Interventional Cardiology, 2008 - Present

• Mercy Hospital St. Louis

• Sub-Investigator - A prospective, open-label, multi-center, observational, single-arm registry to assess physician-determined XIENCE V EECSS acute performance, deliverability and resource utilization. (Abbott Vascular, Inc., Santa Clara, CA). 2008-2009.
• Principal Investigator - A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronoary Syndrome (ATLAS ACS 2 TIMI 51 Trial). (Johnson & Johnson, Titusville, NJ). 2009-Present.
• Sub-Investigator - A Multicenter, Randomized, Parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically ill patients comparing Rivaroxaban with Enoxaparin (MAGELLAN Study). (Bayer Healthcare Pharmaceuticals, Montville, NJ). 2009-Present.
• Sub-Investigator - Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in Patients with Atrial Fibrillation Versus Long Term Warfarin Therapy (PREVAIL)
• Co-Principal Investigator – Prospective - Randomized investigation to Evaluate incidence of headache reduction in subjects with Migraine and PFO Using the AMPLATZER PFO Occluder compared to Medical Management (PREMIUM)
• Sub-Investigator - A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.
• Principal Investigator - Multicenter, randomized, open-label active-controlled study to compare the efficacy and feasibility of the Transradial approach to PCI in women compared with the Transfemoral approach. (SAFE-PCI) 2012 - Present
• Principal Investigator - Treatment with ADP receptor iNhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome Registry participation. (TRANSLATE) 2010 - Present
• Sub-Investigator - PFO Consortium Registry Multicenter prospective non-randomized study with scheduled 3 years follow-up of patients with PFO and ischemic stroke or TIA. 2012 - Present
• Sub-Investigator - Multicenter, randomized, parallel group efficacy and safety study for the prevention of VTE in hospitalized medically ill patients comparing rivaroxaban with enoxaparin (MAGELLAN) 2012 - Present

• Missouri, 2006018676
• Massachusetts, #213219 (expired)

02/27/1974